期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer 被引量:1
1
作者 Yang Liu Wei Xu +5 位作者 Mingxue Li Yueying Yang Dejuan Sun Lidian Chen Hua Li Lixia Chen 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2023年第4期1438-1466,共29页
Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy.Isocitrate dehydrogenases(IDHs)are a class of key proteins in energy me... Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy.Isocitrate dehydrogenases(IDHs)are a class of key proteins in energy metabolism,including IDH1,IDH2,and IDH3,which are involved in the oxidative decarboxylation of isocitrate to yield a-ketoglutarate(a-KG).Mutants of IDH1 or IDH2 can produce D-2-hydroxyglutarate(D-2HG)with a-KG as the substrate,and then mediate the occurrence and development of cancer.At present,no IDH3 mutation has been reported.The results of pan-cancer research showed that IDH1 has a higher mutation frequency and involves more cancer types than IDH2,implying IDH1 as a promising anti-cancer target.Therefore,in this review,we summarized the regulatory mechanisms of IDH1 on cancer from four aspects:metabolic reprogramming,epigenetics,immune microenvironment,and phenotypic changes,which will provide guidance for the understanding of IDH1 and exploring leading-edge targeted treatment strategies.In addition,we also reviewed available IDH1 inhibitors so far.The detailed clinical trial results and diverse structures of preclinical candidates illustrated here will provide a deep insight into the research for the treatment of IDH1-related cancers. 展开更多
关键词 idh1 CANCER Regulatory mechanisms idh1 inhibitors D-2HG Metabolic reprogramming EPIGENETICS Immune microenvironment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部